Home » Topics » Disease categories and therapies » Nephrology

Nephrology
RSS

VPA-985 characterized as potent, selective, orally active V2 antagonist

Nov. 13, 1998

Sepracor announces results of phase II pilot trial for (S)-oxybutynin

Nov. 13, 1998

RenaGel available this month in the U.S.

Nov. 11, 1998

Alza focuses on urology products; licenses Urispas

Nov. 4, 1998

U.S. grants first approval for GelTex's novel phosphate-binding polymer therapeutic

Nov. 3, 1998

Synthelabo team presents new agents for incontinence

Nov. 3, 1998

Basis of beneficial effects of cactus flower in BPH

Oct. 30, 1998

Milkhaus successfully completes phase II trial of BPH therapeutic

Oct. 21, 1998

Celsion ready to begin BPH treatment studies

Oct. 20, 1998

Boston Scientific to copromote Targis System for BPH

Oct. 16, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...